Wobble Genomics: In the Spotlight
Stay informed with our latest updates, industry news, and publications.
Wobble Genomics: In the Spotlight
Stay informed with our latest updates, industry news, and publications.
Wobble Genomics: In the Spotlight
Stay informed with our latest updates, industry news, and publications.
October 17, 2025
ESMO Berlin Conference 2025 Poster
Share
Wobble Genomics, a biotechnology company working to improve outcomes in cancer through better diagnosis and therapy selection, via a novel ultra-sensitive cell-free RNA (cfRNA) liquid biopsy diagnostic platform, today announced the presentation of new data at the European Society for Medical Oncology (ESMO) 2025 Congress.
The study establishes the feasibility and analytical robustness of a novel long-read RNA sequencing assay for detecting low-abundance RNA in blood. The technology has allowed for sensitive detection across a broad RNA size spectrum.
The method identified novel isoforms of key cancer genes HER2 and TROP2 in patient blood samples, allowing more effective ADC development and more accurate patient stratification.
Dr. Richard Kuo, Wobble Genomics CEO and Founder, said: “Our new platforms mark a major breakthrough in liquid biopsy technology, delivering highly sensitive and accurate detection of cancer transcripts directly from whole blood. The promising data shared today represents an important step towards establishing an effective diagnostic tool, transforming how cancers are treated.”
Our latest data demonstrates a limit of detection more than an order of magnitude better than the current industry benchmark, while maintaining 100% molecular specificity at that level of sensitivity
This research demonstrates the potential of liquid biopsy to enable more precise, non-invasive treatment selection, helping match patients to the most effective therapies while reducing reliance on invasive tissue biopsies.
This poster highlights Wobble Genomics’ long-read RNA sequencing platform for precise profiling of HER2 expression in breast cancer. By capturing full-length RNA transcripts, the approach enables isoform-level resolution, revealing detailed expression patterns that correlate strongly with standard IHC classifications in tumour tissue. Importantly, the study also demonstrates the potential to assess HER2 status non-invasively from blood samples, addressing a key unmet clinical need. The results show improved diagnostic accuracy and deeper insight into transcript diversity, supporting more informed patient stratification and treatment selection for HER2-targeted therapies.
Wobble Genomics presents a highly sensitive long-read transcriptomics platform for non-invasive profiling of breast cancer from blood. Leveraging its proprietary Level-Up technology, the platform enables comprehensive detection of cancer-specific RNA isoforms, including clinically relevant HER2 variants, with strong concordance to tumour status. The study demonstrates the potential of liquid biopsy to refine patient stratification, expand eligibility for targeted therapies, and monitor treatment response over time—offering a powerful new approach to precision oncology.
